Finasteride treatment alters tissue specific androgen receptor expression in prostate tissues

Prostate

Volumn 74, Issue 9, 2014, Pages 923-932

  Bauman, Tyler M ^a   Sehgal, Priyanka D ^a   Johnson, Karen A ^b   Pier, Thomas ^b   Bruskewitz, Reginald C ^a   Ricke, William A ^a,b   Huang, Wei ^b  

^a University of Wisconsin Health   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

atrophy; BPH; multispectral imaging

Indexed keywords

ANDROGEN RECEPTOR; CYTOKERATIN 5; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CELL HYPERPLASIA; CLINICAL ARTICLE; EPITHELIUM BASAL CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MORPHOMETRICS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE SIZE; RETROSPECTIVE STUDY; TRANSURETHRAL RESECTION;

ATROPHY; BPH; MULTISPECTRAL IMAGING;

5-ALPHA REDUCTASE INHIBITORS; AGED; FINASTERIDE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; KALLIKREINS; KERATIN-5; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; RECEPTORS, ANDROGEN; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES;

EID: 84901020231     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22810     Document Type: Article

References (45)

1. Girman CJ, Jacobsen SJ, Tsukamoto T, Richard F, Garraway WM, Sagnier PP, Guess HA, Rhodes T, Boyle P, Lieber MM,. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998; 51: 428-436.
2. Roehrborn CG, Marks L, Harkaway R,. Enlarged prostate: A landmark national survey of its prevalence and impact on US men and their partners. Prostate Cancer Prostatic Dis 2006; 9: 30-34.
3. Cunha GR, Lung B,. The possible influence of temporal factors in androgenic responsiveness of urogenital tissue recombinants from wild-type and androgen-insensitive (Tfm) mice. J Exp Zool 1978; 205: 181-193.
4. Cunha GR, Ricke W, Thomson A, Marker PC, Risbridger G, Hayward SW, Wang YZ, Donjacour AA, Kurita T,. Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J Steroid Biochem Mol Biol 2004; 92: 221-236.
5. Forchielli E, Dorfman RI,. Separation of Δ4-5α- and Δ4-5β-hydrogenases from rat liver homogenates. J Biol Chem 1956; 223: 443-448.
6. Bruchovsky N, Wilson JD,. The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem 1968; 243: 2012-2021.
7. Saartok T, Dahlberg E, Gustafsson JA,. Relative binding affinity of anabolic-androgenic steroids: Comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin. Endocrinology 1984; 114: 2100-2106.
8. Godoy A, Kawinski E, Li Y, Oka D, Alexiev B, Azzouni F, Titus MA, Mohler JL,. 5α-reductase type 3 expression in human benign and malignant tissues: A comparative analysis during prostate cancer progression. Prostate 2011; 71: 1033-1046.
9. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW,. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest 1993; 92: 903-910.
10. Levine AC, Wang JP, Ren M, Eliashvili E, Russell DW, Kirschenbaum A,. Immunohistochemical localization of steroid 5 alpha-reductase 2 in the human male fetal reproductive tract and adult prostate. J Clin Endocrinol Metab 1996; 81: 384-389.
11. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE,. Steroid 5alpha-reductase deficiency in man: An inherited form of male pseudohermaphroditism. Science 1974; 186: 1213-1215.
12. Walsh PC, Madden JD, Horrod MJ, Goldstein JL, MacDonald PC, Wilson JD,. Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med 1974; 291: 944-949.
13. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, Vaughan ED, Pappas F, Taylor A, Binkowitz B, Ng J,. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992; 327: 1185-1191.
14. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E,. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992; 74: 505-508.
15. Span PN, Völler MC, Smals AG, Sweep FG, Schalken JA, Feneley MR, Kirby RS,. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate. J Urol 1999; 161: 332-337.
16. Rittmaster RS, Magor KE, Manning AP, Norman RW, Lazier CB,. Differential effect of 5 alpha-reductase inhibition and castration on androgen-regulated gene expression in rat prostate. Mol Endocrinol 1991; 5: 1023-1029.
17. Steiner JF,. Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet 1996; 30: 16-27.
18. Byrnes CA, Morton AS, Liss CL, Lippert MC, Gillenwater JY,. Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: A community-based study. Clin Ther 1995; 17: 956-969.
19. Wang MC, Valenzuela LA, Murphy GP, Chu TM,. Purification of a human prostate specific antigen. Investig Urol 1979; 17: 159-163.
20. Huang W, Hennrick K, Drew S,. A colorful future of quantitative pathology: Validation of Vectra technology using chromogenic multiplexed immunohistochemistry and prostate tissue microarrays. Hum Pathol 2013; 44: 29-38.
21. Nicholson TM, Sehgal PD, Drew SA, Huang W, Ricke WA,. Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment. Differentiation 2013; 85: 140-149.
22. De Marzo AM, Marchi VL, Epstain JI, Nelson WG,. Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis. Am J Pathol 1999; 155: 1985-1992.
23. Claessens F, Verrijdt G, Schoenmakers E, Haelens A, Peeters B, Verhoeven G, Rombauts W,. Selective DNA binding by the androgen receptor as a mechanism for hormone-specific gene regulation. J Steroid Biochem Mol Biol 2001; 76: 23-30.
24. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS,. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192-1202.
25. Thompson IM, Goodman PJ, Tangen CM, Parnes HL, Minasian LM, Godley PA, Lucia MS, Ford LG,. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med 2013; 369: 603-610.
26. Dey P,. Cancer nucleus: Morphology and beyond. Diagn Cytopathol 2010; 38: 382-390.
27. Wang LG, Liu XM, Kreis W, Budman DR,. Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells. Cancer Res 1997; 57: 714-719.
28. Hsieh JT, Chen SC, Yu HJ, Chang HC,. Finasteride upregulates expression of androgen receptor in hyperplastic prostate and LNCaP cells: Implications for chemoprevention of prostate cancer. Prostate 2011; 71: 1115-1121.
29. Donjacour AA, Cunha GR,. Assessment of prostatic protein secretion in tissue recombinants made of urogenital sinus mesenchyme and urothelium from normal or androgen-insensitive mice. Endocrinology 1993; 132: 2342-2350.
30. Simanainen U, Allan CM, Lim P, McPherson S, Jimenez M, Zajac JD, Davey RA, Handelsman DJ,. Disruption of prostate epithelial androgen receptor impedes prostate lobe-specific growth and function. Endocrinology 2007; 148: 2264-2272.
31. Wu CT, Altuwaijri S, Ricke WA, Huang SP, Yeh S, Zhang C, Niu Y, Tsai MY, Chang C,. Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor. Proc Natl Acad Sci USA 2007; 104: 12679-12684.
32. Yang Q, Fung KM, Day WV, Kropp BP, Lin HK,. Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival. Cancer Cell Int 2005; 5: 8.
33. Stanbrough M, Leav I, Kwan PW, Bubley GJ, Balk SP,. Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc Natl Acad Sci USA 2001; 98: 10823-10828.
34. Ricke EA, Williams K, Lee YF, Couto S, Wang Y, Hayward SW, Cunha GR, Ricke WA,. Androgen hormone action in prostatic carcinogenesis: Stromal androgen receptors mediate prostate cancer progression, malignant transformation and metastasis. Carcinogenesis 2012; 33: 1391-1398.
35. Feneley MR, Span PN, Schalken JA, Harper M, Griffiths K, Holmes K, Kirby RS,. A prospective randomized trial evaluating tissue effects of finasteride therapy in benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1999; 2: 277-281.
36. Yang XJ, Lecksell I, Short K, Gottesman J, Peterson L, Bannow J, Schellhammer PF, Fitch WP, Hodge GB, Parra R, Rouse S, Waldstreicher J, Epstein JI,. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology 1999; 53: 696-700.
37. Rittmaster RS, Norman RW, Thomas LN, Rowden G,. Evidence for atrophy and apoptosis in the prostates of men given finasteride. J Clin Endocrinol Metab 1996; 81: 814-819.
38. Montironi R, Valli M, Fabris G,. Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor: Morphological changes in patients who fail to respond. J Clin Pathol 1996; 49: 324-328.
39. Ellem SJ, Schmitt JF, Pedersen JS, Frydenberg M, Risbridger GP,. Local aromatase expression in human prostate is altered in malignancy. J Clin Endocrinol Metab 2004; 89: 2434-2441.
40. Risbridger GP, Wang H, Frydenberg M, Cunha G,. The metaplastic effects of estrogen on mouse prostate epithelium: Proliferation of cells with basal cell phenotype. Endocrinology 2001; 142: 2443-2450.
41. Nicholson TM, Ricke EA, Marker PC, Miano JM, Mayer RD, Timms BG, vom Saal FS, Wood RW, Ricke WA,. Testosterone and 17beta-estradiol induce glandular prostatic growth, bladder outlet obstruction, and voiding dysfunction in male mice. Endocrinology 2012; 153: 5556-5565.
42. Nicholson TM, Ricke WA,. Androgens and estrogens in benign prostatic hyperplasia: Past, present and future. Differentiation 2011; 82: 184-199.
43. Lamb JC, English H, Levandoski PL, Rhodes GR, Johnson RK, Isaacs JT,. Prostatic involution in rats induced by a novel 5 alpha-reductase inhibitor, SK&F 105657: Role for testosterone in the androgenic response. Endocrinology 1992; 130: 685-694.
44. Kurita T, Wang YZ, Donjacour AA, Zhao C, Lydon JP, O'Malley BW, Isaacs JT, Dahiya R, Cunha GR,. Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death Differ 2001; 8: 192-200.
45. Cunha GR, Donjacour AA,. Mesenchymal-epithelial interactions in the growth and development of the prostate. Cancer Treat Res 1989; 46: 159-175.